Verona Pharma to Present at Upcoming Investor Conferences

LONDON, May 30, 2018 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM:VRP) (Nasdaq:VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for respiratory diseases, announces today that Company Management will present at the following upcoming investor conferences:

Event: Jefferies 2018 Global Healthcare Conference
Presenter: Jan-Anders Karlsson, Chief Executive Officer and Executive Director
Date: June 6, 2018
Time: 1:30 PM EDT
Location: New York, NY

Event: JMP Life Science Conference
Presenter: Piers Morgan, Chief Financial Officer
Date: June 20, 2018
Time: 12:30 PM EDT
Location: New York, NY

For more information please visit www.veronapharma.com

About Verona Pharma plc

Verona Pharma is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for the treatment of respiratory diseases with significant unmet medical needs. Verona Pharma’s product candidate, RPL554, is a first-in-class, inhaled, dual inhibitor of the enzymes phosphodiesterase 3 and 4 that acts as both a bronchodilator and an anti-inflammatory agent in a single compound. In clinical trials, treatment with RPL554 has shown clinically meaningful and statistically significant improvements in lung function and clinical symptoms as compared to placebo, and has shown statistically significant improvements in lung function when administered in addition to frequently used short- and long-acting bronchodilators as compared to such bronchodilators administered as a single agent. Verona Pharma is developing RPL554 for the treatment of chronic obstructive pulmonary disease (COPD), cystic fibrosis (CF), and potentially asthma.

For further information, please contact: